Antiemetic effectiveness and safety of aprepitant in patients with lung cancer receiving combination therapy with carboplatin.

Antiemetic effectiveness and safety of aprepitant in patients with lung cancer receiving combination therapy with carboplatin. - Antiemetic effectiveness of aprepitant in patients recieving combination therapy with carboplatin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010018

Enrollment

134

Registered

2013-02-13

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

In initial treatment, patients are randomly allocated to receive newly antiemetic therapy with aprepitant or to recieve existing antiemetic therapy. In second treatment, all patients are received apre

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pathologically confirmed inoperable stage IIIB or stage IV NSCLC Adequate function of the bone marrow, liver and kidney. Patients who can give a precise answer to a questionnaire about antiemetic effect.

Exclusion criteria

Exclusion criteria: Patients with severe complications. Patients with nausea and vomitting in the 24 hours before chemotherapy. Patients received antiemetic therapy in the 48 hours before chemotherapy. Patients with a risk of vomitting for other reasons. (active peptic ulcer and gastrointestinal obstruction, etc)

Design outcomes

Primary

Measure	Time frame
antiemetic effect	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026